NCT05789771 (ATLANT) is a clinical trial of Abemaciclib in HR+/HER2- Breast Cancer, sponsored by Blokhin's Russian Cancer Research Center.

Who is sponsoring NCT05789771?

NCT05789771 is sponsored by Blokhin's Russian Cancer Research Center.

What drugs are being tested in NCT05789771?

Interventions in NCT05789771: Abemaciclib, Abemaciclib, Abemaciclib.

What condition does NCT05789771 study?

NCT05789771 studies HR+/HER2- Breast Cancer, Metastatic Disease, Аdvanced Disease.

Is NCT05789771 still recruiting?

NCT05789771 is currently completed. Last updated 31 March 2023.

Last reviewed 2023-03-31 · How we verify

NCT05789771: ATLANT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.

Completed Last updated 31 March 2023

What this trial tests

trial testing Abemaciclib in HR+/HER2- Breast Cancer in 136 participants. Completed in 1 December 2022.

Timeline

1 April 2022

Primary endpoint
1 December 2022

1 December 2022

Quick facts

Lead sponsor	Blokhin's Russian Cancer Research Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	136
Start date	1 April 2022
Primary completion	1 December 2022
Estimated completion	1 December 2022
Sites	1 location across Russia

Drugs / interventions tested

Abemaciclib (abemaciclib) — full drug profile →
Abemaciclib (abemaciclib) — full drug profile →
Abemaciclib (abemaciclib) — full drug profile →

Conditions studied

HR+/HER2- Breast Cancer — all drugs for HR+/HER2- Breast Cancer →
Metastatic Disease — all drugs for Metastatic Disease →
Аdvanced Disease — all drugs for Аdvanced Disease →

Sponsor

Blokhin's Russian Cancer Research Center — full company profile →

Who can join

18 and older, any sex, with HR+/HER2- Breast Cancer or Metastatic Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The ATLANT study is prospective, multicentre, non-interventional, observational study. Patients with HR+/HER2-negative metastatic breast cancer received abemaciclib as monotherapy or in combination with endocrine therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Abemaciclib

Trials testing the same drug.

NCT07492641 — BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT07428018 — Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Onco · Phase 2 · not yet recruiting
NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
NCT06498648 — Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tis · Phase 1, PHASE2 · recruiting
NCT07441369 — Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer · Phase 2 · enrolling by invitation

Other recruiting trials for HR+/HER2- Breast Cancer

Currently open trials in the same condition.

NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
NCT06967103 — QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer · Phase 2 · recruiting
NCT06874933 — Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) · Phase 2 · recruiting
NCT06860529 — Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer · Phase 2 · recruiting
NCT06977893 — Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Paralle · Phase 3 · recruiting

Other Blokhin's Russian Cancer Research Center trials

Trials by the same sponsor.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07448662 — Local Treatment Strategies for Brain Metastases of Colorectal Cancer · active not recruiting
NCT06967155 — A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metasta · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05789771 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Blokhin's Russian Cancer Research Center
Last refreshed: 31 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05789771.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing